Clinical Trial Update: Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869 [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of ABT-869 (linifanib) evaluating the effects of food and diurnal variation on drug exposure in adults with advanced solid tumors;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ABT-869 (linifanib)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED